Wechselwirkungen · Janumet
Janumet 50 mg/850 mg film-coated tablets Janumet 50 mg/1 000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-119365 · Präparat HOS-094931
Concomitant use of medicinal products that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis. Consider the benefits and risks of concomitant use. Close monitoring of glycaemic control, dose adjustment within the recommended posology and changes in diabetic treatment should be considered when such products are co-administered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) dolutegravir (HOS-089992) ranolazine (HOS-086141) vandetanib (HOS-119366)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-10T16:51:00Z · SHA-256 7ab5484fea0dbb19060d54dea7052ed288c9ae1559061c17e0fa301f89920bd6 · Passage 73a3dfccc9e946681a07cf00795a14cf3f7915edf2b81f35effffc40ba08f7f9 · Zeichen 1352–1979 im Abschnitt